CSC
ABBV icon

Caldwell Sutter Capital’s AbbVie ABBV Stock Holding History

Caldwell Sutter Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Sell
5,123
-240
-4% -$53.2K 0.45% 54
2025
Q4 		$1.23M Sell
5,363
-53
-1% -$12.1K 0.52% 47
2025
Q3 		$1.25M Sell
5,416
-619
-10% -$126K 0.54% 44
2025
Q2 		$1.12M Buy
6,035
+72
+1% +$13.4K 0.51% 47
2025
Q1 		$1.25M Sell
5,963
-227
-4% -$44.1K 0.59% 42
2024
Q4 		$1.1M Buy
6,190
+649
+12% +$119K 0.51% 51
2024
Q3 		$1.09M Sell
5,541
-201
-4% -$37.5K 0.51% 50
2024
Q2 		$985K Sell
5,742
-105
-2% -$17.4K 0.49% 53
2024
Q1 		$1.06M Sell
5,847
-344
-6% -$59.3K 0.51% 56
2023
Q4 		$959K Sell
6,191
-114
-2% -$16.6K 0.49% 59
2023
Q3 		$940K Buy
6,305
+38
+0.6% +$5.58K 0.52% 53
2023
Q2 		$844K Buy
6,267
+2,499
+66% +$366K 0.44% 66
2023
Q1 		$601K Buy
3,768
+1,988
+112% +$304K 0.44% 58
2022
Q4 		$288K Buy
+1,780
New +$273K 0.25% 83

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caldwell Sutter Capital's ABBV Position: Q1 2026 in Review

Caldwell Sutter Capital reduced its AbbVie (ABBV) stake by 4.5% in Q1 2026, selling an estimated $53.2K and leaving 5,123 shares worth $1.11M. The position accounts for 0.45% of the portfolio, ranked #54.

Caldwell Sutter Capital first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.25M in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Caldwell Sutter Capital held 5,123 shares of AbbVie worth $1.11M as of Q1 2026.
  • Caldwell Sutter Capital sold 240 AbbVie shares in Q1 2026, an estimated $53.2K.
  • AbbVie made up 0.45% of Caldwell Sutter Capital's portfolio in Q1 2026, its #54 holding.
  • Caldwell Sutter Capital first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • Caldwell Sutter Capital's AbbVie position peaked at $1.25M in Q3 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Caldwell Sutter Capital's 13F filing for Q1 2026, filed 6 May 2026.